Arrowstreet Capital
VERV

Arrowstreet Capital’s Verve Therapeutics VERV Stock Holding History

Arrowstreet Capital’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-49,536
Closed -$556K – 2125
2025
Q2 		$556K Buy
+49,536
New +$282K ﹤0.01% 1732
2024
Q3 		– Sell
-59,861
Closed -$292K – 1887
2024
Q2 		$292K Sell
59,861
-7,835
-12% -$49.2K ﹤0.01% 1402
2024
Q1 		$899K Buy
+67,696
New +$898K ﹤0.01% 1342

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Arrowstreet Capital's VERV Position: Q3 2025 in Review

Arrowstreet Capital sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 49,536 shares — an estimated $556K sold.

Arrowstreet Capital first reported a position in VERV in Q1 2024 and held it in 3 quarters. The position peaked at $899K in Q1 2024. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Arrowstreet Capital reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Arrowstreet Capital sold 49,536 Verve Therapeutics shares in Q3 2025, an estimated $556K.
  • Arrowstreet Capital first reported a position in Verve Therapeutics in Q1 2024 and held it in 3 quarters.
  • Arrowstreet Capital's Verve Therapeutics position peaked at $899K in Q1 2024.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Arrowstreet Capital's 13F filing for Q3 2025, filed 13 Nov 2025.